JW Pharma is speeding up the development of Dumirox·Actemra

Dumirox has been approved for AMC's Sponsor-Investigator Trials

Actemra begins prescribing as treatment for COVID-19 In UK

Self-developed CWP291, excellent treatment effect for COVID-19 infected hamsters

Dumirox and Actemra, which are monopolized by JW Pharma's domestic development and copyright, are emerging as a possible treatment for COVID-19 On the 8th, the MFDS approved sponsor-investigator trials for patients with COVID-19 of Dumirox 100mg (Fluvoxamine maleate), an antidepressant drug.

 

With the approval of this clinical plan, AMC will conduct a randomized, placebo-controlled method to investigate the treatment effect of Fluvoxamine maleate for 406 mild COVID-19 patients admitted to the Community Treatment Centers.

 

Dumirox is a selective serotonin reuptake inhibitor as an antidepressant primarily prescribed for patients with depression and obsessive-compulsive disorder.

 

It was developed by Abbott in the United States, and JW Pharma secures the exclusive copyright in Korea.

 

It is widely known as Luvox abroad.

 

Dumirox has already proven the effectiveness of COVID-19 treatment in overseas clinical trials.

 

According to the online edition of the Journal of American Medical Association on November 12 last year, research has shown that Dumirox can help prevent the condition from becoming severe by significantly reducing the likelihood of hospitalization for patients with COVID-19.

 

Eric Lenze, Wallace and Lucille K.

 

Renard Professor of Psychiatry at the University of Washington School of Medicine, USA, conducted a clinical trial in Illinois and Missouri in 152 patients with COVID-19, mild to moderate, aged 18 years or older, in self-isolation at home.

 

"Six out of 72 people who took placebo were classified as severely ill, whereas all 80 people taking Dumirox did not get worse," the research team said.

 

"We found that Dumirox may reduce the risk of hospitalization and death in patients with COVID-19." Rheumatoid arthritis treatment Actemra (Tocilizumab) has been shown to lower the mortality rate of critically ill patients with COVID-19 abroad, and the UK government recommended that the treatment be prescribed for the treatment of COVID-19 starting on the 8th (local time).

 

According to the Guardian on the 7th, a study by the Remap-Cap research team showed that the mortality rate of the group receiving general treatment was 35.8%, while the mortality rate of those receiving Actemra treatment was 28%.

 

In addition, patients injected with Actemra left the intensive care unit 7 to 10 days earlier than the control group.

 

In September of last year, global pharmaceutical company Roche unveiled the results of EMPACTA, the second global phase III clinical trial of Actemra, a rheumatoid arthritis treatment to be developed as a treatment for COVID-19.

 

A total of 389 patients were studied, and the risk of dying or wearing a ventilator was 44% lower than that of placebo.

 

The third global phase III clinical trial REMDACTA, which Roche is in cooperation with Gilead Sciences, is also raising expectations.

 

REMDACTA is a trial that evaluates efficacy and safety as a combination therapy of Remdesivir and Actemra, and has been in progress on a total of 450 COVID-19 patients since June of last year.

 

JW Pharma is developing a treatment for COVID-19 through its own new drug strategy.

 

JW Pharma recently secured the right to own and use the results of a study on COVID-19 infection animal model of CWP291 from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), and entered the subsequent development stage.

 

As a result of the efficacy evaluation for the golden hamster of CWP291, a high rate of improvement in lung lesions was shown, and an excellent reduction effect was also confirmed in the amount of virus remaining in the lung tissue (PCR).

 

This can be judged as the result obtained by the GRP78 binding mechanism that CWP291 was identified in the clinical phase I study of the existing target anticancer drug.

 

GRP78 is reported as a host factor for several single-stranded RNA viruses, including COVID-19, MERS, Dengue, Zika, and Japanese encephalitis in many academic data.